This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 8
  • /
  • Opdivo indication for hepatocellular carcinoma (li...

Opdivo indication for hepatocellular carcinoma (liver cancer) withdrawn from FDA.- BMS

Read time: 1 mins
Published:1st Aug 2021

The company took this action following the Agency’s industry-wide evaluation of accelerated approvals for checkpoint inhibitors that have not met their post-marketing requirements demonstrating confirmatory benefit. This included a meeting of the Oncologic Drugs Advisory Committee in April and subsequent discussion with the FDA.

Opdivo has been withdrawn earlier for this indication in Europe .

Condition: Liver Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.